LDN Conference 2013 – Chicago
Date: October 5th 2013
Time: 8.30 Registration, 9am – 5pm
Place: Harper College, Palatine Illinois US
Cost: $80 per head which includes: the conference, lunch, refreshments and Friday Night Networking Party.
Early booking is advised to avoid disappointment as spaces are limited.
The conference reviews, compares and contrasts the most recent data and treatments for a variety of Auto-Immune and Immuno-modulated Conditions
Speakers Paul Battle PA-C, Dr. Burt Berkson , Dr Pradeep Chopra, Dr Patrick Crowley, Professor Angus Dalgleish, Pharmacist Stephen Dickson, Dr Tom Gilhooly,, Pharmacist Dr. Mark H. Mandel, Dr Mark Shukhman, Dr. Deanna Windham, Jackie Young-Bihari widow of Dr Bernard Bihari and Patron of the LDN Research Trust. Linda Elsegood Trustee of the LDN Research Trust.
Conference website: http://ldn2013.com
Dr Pradeep Chopra MD, Pain Specialist from Rhode Island said “Naltrexone is an opiate antagonist drug (blocks the effect of morphine-like drugs) which was developed in the 1970s and approved by the FDA in 1984. It has since been shown to offer benefits at low doses (low dose naltrexone or LDN) for a wide range of conditions including pain, Parkinson’s disease, MS, Alzheimer’s disease, HIV, and various autoimmune conditions.
Formal clinical trials and publications for LDN are few, and FDA approval for using naltrexone in these medical conditions is lacking, hence LDN has not been embraced by mainstream medicine. Pharmaceutical companies have no incentives for funding clinical trials on a generic drug that has already been FDA approved and is widely manufactured. LDN is reported to halt disease progression of a number of different conditions, and in some cases has improved symptoms remarkably. However, it does not offer benefits to all patients who try it, although side effects appear to be rare when it is used appropriately. Clinical trials are thus necessary to evaluate potential adverse effects and determine the true efficacy and safety of LDN in specific medical conditions. ”
Notes for Editors
< LDN prescribing doctors, pharmacists and users are happy to be interviewed and supply photographs.
< We would like to offer media passes for the conference.